Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Intra-Cellular Therapies Inc (NASDAQ: ITCI) closed the day trading at $72.30 down -1.31% from the previous closing price of $73.26. In other words, the price has decreased by -$1.31 from its previous closing price. On the day, 0.55 million shares were traded. ITCI stock price reached its highest trading level at $73.821 during the session, while it also had its lowest trading level at $71.9712.
Ratios:
For a better understanding of ITCI, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.31 and its Current Ratio is at 5.41. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on January 03, 2024, initiated with a Outperform rating and assigned the stock a target price of $83.
On December 11, 2023, TD Cowen started tracking the stock assigning a Outperform rating and target price of $75.
On April 20, 2023, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $80.Morgan Stanley initiated its Overweight rating on April 20, 2023, with a $80 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 11 ’24 when Mates Sharon sold 20,565 shares for $65.21 per share. The transaction valued at 1,341,123 led to the insider holds 1,050,309 shares of the business.
Hineline Lawrence J. sold 10,121 shares of ITCI for $667,587 on Mar 11 ’24. The SVP of Finance, CFO now owns 0 shares after completing the transaction at $65.96 per share. On Mar 11 ’24, another insider, Halstead Michael, who serves as the EVP and General Counsel of the company, sold 7,345 shares for $65.97 each. As a result, the insider received 484,537 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ITCI now has a Market Capitalization of 7642977792 and an Enterprise Value of 6518156800. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.24 while its Price-to-Book (P/B) ratio in mrq is 11.78. Its current Enterprise Value per Revenue stands at 14.037 whereas that against EBITDA is -41.033.
Stock Price History:
The Beta on a monthly basis for ITCI is 1.01, which has changed by 0.14290226 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, ITCI has reached a high of $84.89, while it has fallen to a 52-week low of $45.50. The 50-Day Moving Average of the stock is 4.11%, while the 200-Day Moving Average is calculated to be 16.08%.
Shares Statistics:
Over the past 3-months, ITCI traded about 957.69K shares per day on average, while over the past 10 days, ITCI traded about 2240460 shares per day. A total of 104.33M shares are outstanding, with a floating share count of 101.52M. Insiders hold about 2.67% of the company’s shares, while institutions hold 86.54% stake in the company. Shares short for ITCI as of 1713139200 were 3590941 with a Short Ratio of 3.75, compared to 1710460800 on 3307047. Therefore, it implies a Short% of Shares Outstanding of 3590941 and a Short% of Float of 4.2700000000000005.
Earnings Estimates
The current rating of Intra-Cellular Therapies Inc (ITCI) reflects the combined expertise of 14.0 analysts actively engaged in assessing its market performance.On average, analysts expect EPS of -$0.32 for the current quarter, with a high estimate of -$0.24 and a low estimate of -$0.47, while EPS last year was -$0.46. The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.14 and low estimates of -$0.32.
Analysts are recommending an EPS of between -$0.29 and -$1.0 for the fiscal current year, implying an average EPS of -$0.64. EPS for the following year is $1.08, with 14.0 analysts recommending between $3.17 and -$0.46.
Revenue Estimates
13 analysts predict $141.17M in revenue for the current quarter. It ranges from a high estimate of $144.8M to a low estimate of $136.91M. As of the current estimate, Intra-Cellular Therapies Inc’s year-ago sales were $91.98MFor the next quarter, 13 analysts are estimating revenue of $159.37M. There is a high estimate of $165.4M for the next quarter, whereas the lowest estimate is $155.58M.
A total of 15 analysts have provided revenue estimates for ITCI’s current fiscal year. The highest revenue estimate was $681.1M, while the lowest revenue estimate was $652M, resulting in an average revenue estimate of $662.06M. In the same quarter a year ago, actual revenue was $464.37MBased on 15 analysts’ estimates, the company’s revenue will be $921.37M in the next fiscal year. The high estimate is $1.05B and the low estimate is $792M.
